Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

BACKGROUND: Cytomegalovirus end-organ disease can be prevented by giving ganciclovir when viraemia is detected in allograft recipients. Values of viral load correlate with development of end-organ disease and are moderated by pre-existing natural immunity. Our aim was to determine whether vaccine-in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Griffiths, Paul D, Stanton, Anna, McCarrell, Erin, Smith, Colette, Osman, Mohamed, Harber, Mark, Davenport, Andrew, Jones, Gareth, Wheeler, David C, O'Beirne, James, Thorburn, Douglas, Patch, David, Atkinson, Claire E, Pichon, Sylvie, Sweny, Paul, Lanzman, Marisa, Woodford, Elizabeth, Rothwell, Emily, Old, Natasha, Kinyanjui, Ruth, Haque, Tanzina, Atabani, Sowsan, Luck, Suzanne, Prideaux, Steven, Milne, Richard SB, Emery, Vincent C, Burroughs, Andrew K
Formato: Artigo
Idioma:Inglês
Publicado em: Lancet Publishing Group 2011
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3075549/
https://ncbi.nlm.nih.gov/pubmed/21481708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(11)60136-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados